Holen Sie sich die Stockscreener-App
24.18
1.10%
-0.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.45
Offen:
$24.67
24-Stunden-Volumen:
7.71M
Relative Volume:
1.33
Marktkapitalisierung:
$12.42B
Einnahmen:
$11.89B
Nettoeinkommen (Verlust:
$-560.00M
KGV:
-21.98
EPS:
-1.1
Netto-Cashflow:
$191.00M
1W Leistung:
+2.07%
1M Leistung:
-14.41%
6M Leistung:
-21.54%
1J Leistung:
-32.33%
1-Tages-Spanne:
$24.04
$24.85
1-Wochen-Bereich:
$23.28
$24.85
52-Wochen-Spanne:
$21.33
$40.49
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
24.18 | 12.56B | 11.89B | -560.00M | 191.00M | -1.10 |
|
ISRG
Intuitive Surgical Inc
|
480.26 | 171.02B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.94 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
87.71 | 42.93B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
284.89 | 41.69B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.20 | 17.70B | 2.90B | 467.20M | 306.90M | 6.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Forsta AP Fonden Sells 188,100 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Precision Trading with Baxter International Inc. (BAX) Risk Zones - news.stocktradersdaily.com
Baxter's Novum IQ Infusion Pump Safety Crisis: Implications for Medical Device Investors - AInvest
Is There An Opportunity With Baxter International Inc.'s (NYSE:BAX) 33% Undervaluation? - au.finance.yahoo.com
Baxter International Inc. (NYSE:BAX) Shares Sold by Russell Investments Group Ltd. - MarketBeat
Trend Dashboard Flags Baxter International Inc. As Potential Swing TradeJuly 2025 Weekly Recap & Real-Time Price Movement Reports - beatles.ru
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Baxter downgraded to Hold at Stifel on weak Q2 report - MSN
Baxter International (BAX) Is Up 7.2% After Profitable Q2 and Raised Sales GuidanceWhat's Changed - simplywall.st
Here’s Why You Should Consider Selling Your Baxter (BAX) Shares - Insider Monkey
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - Yahoo Finance
Baxter to split into two companies - The Covington News
Morgan Stanley Keeps Sell Rating on Baxter International with $19 Target - AInvest
Baxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing - Fierce Healthcare
Baxter International (BAX) Is Up 7.9% After Reversing Losses and Reaffirming 2025 Sales Growth Outlook - simplywall.st
UBS Group Cuts Baxter International (NYSE:BAX) Price Target to $24.00 - MarketBeat
Baxter International's GF Score Indicates Potential for Underperformance - AInvest
FDA's IV Shortage Resolution Lifts Baxter's Volume to 394th Rank as Stock Rises 0.64% - AInvest
Barclays Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter International's (BAX) Hold Rating Reiterated at Stifel Nicolaus - MarketBeat
Arkadios Wealth Advisors Acquires Shares of 17,245 Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. shares rise 1.98% intraday after ATS Corporation reported Q1 revenue growth and provided Q2 revenue guidance. - AInvest
Baxter International Inc. (NYSE:BAX) Shares Bought by Raiffeisen Bank International AG - MarketBeat
Are Wall Street Analysts Bullish on Baxter International Stock? - MSN
LSV Asset Management Sells 391,800 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International 2025 Q2 Earnings Strong Turnaround as Net Income Surges 129% - AInvest
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast - MSN
Baxter International Inc. (BAX): A Bull Case Theory - Insider Monkey
Wall Street Zen Downgrades Baxter International (NYSE:BAX) to Hold - MarketBeat
Baxter International Surges 1.78% on $330M Volume Ranking 363rd as Tactical Strategy Outperforms Benchmark by 137.53 Pts - AInvest
Baxter stock rises on earnings beat, guidance raise - MSN
Baxter International (NYSE:BAX) Updates FY 2025 Earnings Guidance - MarketBeat
Baxter International (NYSE:BAX) Downgraded by The Goldman Sachs Group to "Neutral" - MarketBeat
Stifel Downgrades Baxter International (BAX) - MSN
Baxter slashes its profit forecast after disappointing quarter - Medical Buyer
Barclays Lowers Price Target on Baxter International to $36 From $41, Maintains Overweight Rating - MarketScreener
Baxter downgraded at Stifel on weak Q2 report (BAX:NYSE) - Seeking Alpha
Stifel downgrades Baxter as it sees longer path to recovery under new CEO - Investing.com Canada
Baxter’s shares fall 23% following tepid Q2 2025 financials - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Baxter slumps as Medical Products & Therapies drive Q2 revenue miss - MSN
Stifel Downgrades Baxter International to Hold From Buy, Adjusts Price Target to $25 From $36 - MarketScreener
Baxter International (NYSE:BAX) Hits New 52-Week Low After Earnings Miss - MarketBeat
Baxter: Stifel downgrades to ’Hold’, cuts PT on disappointing Q2 results - Investing.com
What is Baxter International Inc. company’s growth strategyRemarkable growth - Jammu Links News
How does Baxter International Inc. compare to its industry peersCapitalize on emerging trends for profits - Jammu Links News
Baxter International (NYSE:BAX) Updates Q3 2025 Earnings Guidance - MarketBeat
How strong is Baxter International Inc. company’s balance sheetMaximize profits with strategic stock selection - Jammu Links News
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):